Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy.

BMJ Open · 2015 · PMC4499745 · PMID 26137881

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

likely to be significantno p-value reported

The potential economic impact of erlotinib use in the 60% of patients who develop rash is likely to be significant for the UK National Health Service (NHS).

also in 1,824 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.